Stromedix (acq. by Biogen)
Investment Year
2008
Exit
2012
Sector
Geography
North America - East
Website
www.stromedix.com

Stromedix (acq. by Biogen)

Stromedix's initial focus is on chronic indications and plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.  In 2012, Stromedix was acquired by Biogen Idec (NASDAQ: BIIB).

News